23.84
+2.58%
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Neuren Pharmaceuticals
Its shares trade on ASX under the ticker NEU.AX. It has been listed since 3 February 2005. In the fiscal year to 31 December 2025, it reported net income of A$30.4m. At that date it held total assets of A$342.9m and shareholders' equity of A$338.5m.
Neuren Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment, and neurodegenerative disorders. The company is headquartered in Melbourne, Victoria. The company went IPO on 2005-02-03. The firm is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. The Company’s product DAYBUE (trofinetide) is used to treat Rett syndrome in adults and pediatric patients two years of age and older. The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted orphan drug designation to the Company for trofinetide in Fragile X syndrome. Its second product NNZ-2591 is in phase II clinical trials in Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. The firm has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of trofinetide.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 3 Feb 2005
- Website
- neurenpharma.com ↗
Leadership
Pay as last reported
- Mr. Patrick DaviesNon-Executive Independent Chairman of the BoardA$125,000
- Mr. Jonathan PilcherChief Executive Officer, Managing Director, Executive Director, since 2013A$1.4m
- Ms. Lauren FrazerChief Financial Officer, Company Secretary
- Mr. Larry GlassChief Science Officer, since 2009NZD 405,000
- Dr. Clive BlowerVice President - Product Development
- Mr. Gerry ZhaoVice President - Corporate Development
- Ms. Liza SquiresChief Medical Officer
- Ms. Dianne AngusNon-Executive Independent DirectorA$75,000
- Mr. Joseph BasileNon-Executive Independent DirectorA$62,500
- Dr. Jenny HarryNon-Executive Independent DirectorA$75,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 43
- Environment
- 50
- Social
- 8
- Governance
- 70
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Neuren Pharmaceuticals Ltd. develops innovative therapies for neurological disorders with limited treatment options.
- DAYBUE (trofinetide) is approved for Rett syndrome in adults and pediatric patients two years and older.
- The company has secured orphan drug designations from FDA and EMA for trofinetide in Fragile X syndrome.
Weaknesses
- Neuren's second product NNZ-2591 is still in phase II clinical trials for multiple syndromes.
- The company relies on Acadia Pharmaceuticals for the development and commercialization of trofinetide.
- Neuren's business is focused on a narrow segment of neurological disorders.
Opportunities
- The firm has potential for expanding trofinetide's use in Fragile X syndrome with FDA and EMA support.
- NNZ-2591 in phase II trials could lead to new treatments for Phelan-McDermid syndrome.
- The orphan drug designations may accelerate regulatory approvals for future products.
Threats
- The clinical trial results for NNZ-2591 could fail to meet efficacy standards.
- Acadia Pharmaceuticals might not fully commercialize trofinetide as expected.
- Regulatory changes could impact orphan drug designations for future therapies.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.